{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:05:45Z","timestamp":1790136345412,"version":"4.0.1"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40262-025-01511-6","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T03:30:30Z","timestamp":1746847830000},"page":"815-848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Impact of Dietary Interventions on the Pharmacokinetics of Antifungal Drugs: A Systematic Review with Meta-analyses"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4926-6120","authenticated-orcid":false,"given":"Agnieszka","family":"Wiesner-Kie\u0142czewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-036X","authenticated-orcid":false,"given":"Pawe\u0142","family":"Zagrodzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-4492","authenticated-orcid":false,"given":"Pawe\u0142","family":"Pa\u015bko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"1511_CR1","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","volume":"24","author":"DW Denning","year":"2024","unstructured":"Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24:e428\u201338.","journal-title":"Lancet Infect Dis"},{"key":"1511_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13601-020-00353-8","volume":"10","author":"WG Rapeport","year":"2020","unstructured":"Rapeport WG, Ito K, Denning DW. The role of antifungals in the management of patients with severe asthma. Clin Transl Allergy. 2020;10:46.","journal-title":"Clin Transl Allergy"},{"key":"1511_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.tim.2014.01.001","volume":"22","author":"D Armstrong-James","year":"2014","unstructured":"Armstrong-James D, Meintjes G, Brown GD. A neglected epidemic: fungal infections in HIV\/AIDS. Trends Microbiol. 2014;22:120\u20137.","journal-title":"Trends Microbiol"},{"key":"1511_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.5603\/AHP.a2021.0025","volume":"52","author":"J Styczy\u0144ski","year":"2021","unstructured":"Styczy\u0144ski J, Ga\u0142\u0105zka P, Czy\u017cewski K, Bartoszewicz N, Cisek J, D\u0105browska A, et al. High risk of invasive fungal disease in children undergoing hematopoietic cell transplantation or complex anticancer therapy: adverse role of post-transplant CMV replication. Acta Haematol Pol. 2021;52:483\u201392.","journal-title":"Acta Haematol Pol"},{"key":"1511_CR5","doi-asserted-by":"publisher","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","volume":"4","author":"PG Pappas","year":"2018","unstructured":"Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Prim. 2018;4:18026.","journal-title":"Nat Rev Dis Prim"},{"key":"1511_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","volume":"3","author":"F Bongomin","year":"2017","unstructured":"Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases\u2014estimate precision. J Fungi. 2017;3:57.","journal-title":"J Fungi"},{"key":"1511_CR7","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/S0140-6736(24)01695-7","volume":"404","author":"N van Rhijn","year":"2024","unstructured":"van Rhijn N, Arikan-Akdagli S, Beardsley J, Bongomin F, Chakrabarti A, Chen SCA, et al. Beyond bacteria: the growing threat of antifungal resistance. Lancet. 2024;404:1017\u20138.","journal-title":"Lancet"},{"key":"1511_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1126\/science.aap7999","volume":"360","author":"MC Fisher","year":"2018","unstructured":"Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360:739\u201342.","journal-title":"Science"},{"key":"1511_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.idc.2021.03.003","volume":"35","author":"R Ben-Ami","year":"2021","unstructured":"Ben-Ami R, Kontoyiannis DP. Resistance to antifungal drugs. Infect Dis Clin N Am. 2021;35:279\u2013311.","journal-title":"Infect Dis Clin N Am"},{"key":"1511_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","volume":"20","author":"MC Fisher","year":"2022","unstructured":"Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20:557\u201371.","journal-title":"Nat Rev Microbiol"},{"key":"1511_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s10461-022-03880-6","volume":"27","author":"A Wiesner","year":"2023","unstructured":"Wiesner A, Skro\u0144ska M, Gawlik G, Marcinkowska M, Zagrodzki P, Pa\u015bko P. Interactions of antiretroviral drugs with food, beverages, dietary supplements, and alcohol: a systematic review and meta-analyses. AIDS Behav. 2023;27:1441\u201368.","journal-title":"AIDS Behav"},{"key":"1511_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/jac\/dkae028","volume":"79","author":"A Wiesner","year":"2024","unstructured":"Wiesner A, Zagrodzki P, Pa\u015bko P. Do dietary interventions exert clinically important effects on the bioavailability of beta-lactam antibiotics?\u2014a systematic review with meta-analyses. J Antimicrob Chemother. 2024;79:722\u201357.","journal-title":"J Antimicrob Chemother"},{"key":"1511_CR13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40262-024-01377-0","volume":"63","author":"A Wiesner","year":"2024","unstructured":"Wiesner A, Zagrodzki P, Gawalska A, Pa\u015bko P. Together or apart? Revealing the impact of dietary interventions on bioavailability of quinolones: a systematic review with meta-analyses. Clin Pharmacokinet. 2024;63:773\u2013818.","journal-title":"Clin Pharmacokinet"},{"key":"1511_CR14","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1093\/jac\/dkae315","volume":"79","author":"A Wiesner","year":"2024","unstructured":"Wiesner A, Zagrodzki P, Gawalska A, Pa\u015bko P. Clinically important interactions of macrolides and tetracyclines with dietary interventions\u2014a systematic review with meta-analyses. J Antimicrob Chemother. 2024;79:2762\u201391.","journal-title":"J Antimicrob Chemother"},{"key":"1511_CR15","doi-asserted-by":"publisher","first-page":"e02167","DOI":"10.1128\/AAC.02167-19","volume":"64","author":"KA Mergenhagen","year":"2020","unstructured":"Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. Fact versus fiction: a review of the evidence behind alcohol and antibiotic interactions. Antimicrob Agents Chemother. 2020;64:e02167-e2219.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR16","doi-asserted-by":"crossref","unstructured":"Viecceli C, Mattos ACV, Costa MCB, Melo RB de, Rodrigues T da C, Czepielewski MA. Evaluation of ketoconazole as a treatment for Cushing\u2019s disease in a retrospective cohort. Front Endocrinol (Lausanne). 2022;13:1017331.","DOI":"10.3389\/fendo.2022.1017331"},{"key":"1511_CR17","unstructured":"FDA. FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death. 2016. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm500597.htm Accessed 30 Mar 2025."},{"key":"1511_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jddst.2017.04.017","volume":"42","author":"DR Serrano","year":"2017","unstructured":"Serrano DR, Lalatsa A. Oral amphotericin B: the journey from bench to market. J Drug Deliv Sci Technol. 2017;42:75\u201383.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1511_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114969","volume":"199","author":"F Sousa","year":"2023","unstructured":"Sousa F, Nascimento C, Ferreira D, Reis S, Costa P. Reviving the interest in the versatile drug nystatin: a multitude of strategies to increase its potential as an effective and safe antifungal agent. Adv Drug Deliv Rev. 2023;199: 114969.","journal-title":"Adv Drug Deliv Rev"},{"key":"1511_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"1511_CR21","unstructured":"Higgins JPT, Li T, Sterne JAC. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for crossover trials. Cochrane Methods. 2021;1\u20136."},{"key":"1511_CR22","unstructured":"NIH. Study quality assessment tools. 2022. https:\/\/www.nhlbi.nih.gov\/health\u2010topics\/study\u2010quality\u2010assessment\u2010tools. Accessed 8 Aug 2024."},{"key":"1511_CR23","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1002\/sim.3427","volume":"27","author":"JPT Higgins","year":"2008","unstructured":"Higgins JPT, White IR, Anzures-Cabrera J. Meta-analysis of skewed data: combining results reported on log-transformed or raw scales. Stat Med. 2008;27:6072\u201392.","journal-title":"Stat Med"},{"key":"1511_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"1511_CR25","unstructured":"Deeks J, Higgins J, Altman D. Chapter 10: Analysing data and undertaking meta-analyses. Cochrane Handb Syst Rev Interv version 63. 2022."},{"key":"1511_CR26","first-page":"228","volume":"7","author":"P Lelawongs","year":"1988","unstructured":"Lelawongs P, Barone JA, Colaizzi JL, Hsuan AT, Mechlinski W, Legendre R, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm. 1988;7:228\u201335.","journal-title":"Clin Pharm"},{"key":"1511_CR27","first-page":"131","volume":"33","author":"RA Yeates","year":"1995","unstructured":"Yeates RA, Zimmermann T, Laufen H, Albrecht M, Wildfeuer A. Comparative pharmacokinetics of fluconazole and of itraconazole in Japanese and in German subjects. Int J Clin Pharmacol Ther. 1995;33:131\u20135.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1511_CR28","first-page":"87","volume":"14","author":"T Zimmermann","year":"1994","unstructured":"Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A. Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. Int J Clin Pharmacol Res. 1994;14:87\u201393.","journal-title":"Int J Clin Pharmacol Res"},{"key":"1511_CR29","unstructured":"FDA. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002. https:\/\/www.fda.gov\/files\/drugs\/published\/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf. Accessed 10 Aug 2024."},{"key":"1511_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00134-21","volume":"65","author":"AM Rauseo","year":"2021","unstructured":"Rauseo AM, Mazi P, Lewis P, Burnett B, Mudge S, Spec A. Bioavailability of single-dose SUBA-itraconazole compared to conventional itraconazole under fasted and fed conditions. Antimicrob Agents Chemother. 2021;65: e0013421.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR31","doi-asserted-by":"publisher","first-page":"ofad389","DOI":"10.1093\/ofid\/ofad389","volume":"10","author":"K Benedict","year":"2023","unstructured":"Benedict K, Gold JAW, Toda M, Thompson GR, Wiederhold NP, Smith DJ. Low rates of antifungal therapeutic drug monitoring among inpatients who received itraconazole, posaconazole, or voriconazole, United States, 2019\u20132021. Open Forum Infect Dis. 2023;10:ofad389.","journal-title":"Open Forum Infect Dis"},{"key":"1511_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","volume":"15","author":"J John","year":"2019","unstructured":"John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 2019;15:881\u201395.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1511_CR33","doi-asserted-by":"crossref","unstructured":"Clary RT, Deja E, Rittmann B, Bearman G. Impact of voriconazole therapeutic drug monitoring on adverse effects and clinical outcomes: a literature review. Curr Infect Dis Rep. 2025;27:6.","DOI":"10.1007\/s11908-025-00856-0"},{"key":"1511_CR34","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1128\/AAC.00802-12","volume":"56","author":"MJ Dolton","year":"2012","unstructured":"Dolton MJ, Ray JE, Chen SCA, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012;56:5503\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR35","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1086\/605499","volume":"49","author":"JM Lestner","year":"2009","unstructured":"Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis. 2009;49:928\u201330.","journal-title":"Clin Infect Dis"},{"key":"1511_CR36","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.3390\/molecules27207034","volume":"27","author":"P Aris","year":"2022","unstructured":"Aris P, Wei Y, Mohamadzadeh M, Xia X. Griseofulvin: an updated overview of old and current knowledge. Molecules. 2022;27:7034.","journal-title":"Molecules"},{"key":"1511_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","volume":"22","author":"CY Wu","year":"2005","unstructured":"Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11\u201323.","journal-title":"Pharm Res"},{"issue":"Suppl 1","key":"1511_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol. 2003;56(Suppl 1):17\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"1511_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/ph14030206","volume":"14","author":"A Wiesner","year":"2021","unstructured":"Wiesner A, Gajewska D, Pa\u015bko P. Levothyroxine interactions with food and dietary supplements\u2014a systematic review. Pharmaceuticals. 2021;14:206.","journal-title":"Pharmaceuticals"},{"key":"1511_CR40","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2174\/1570159X19666211116142806","volume":"20","author":"A Wiesner","year":"2022","unstructured":"Wiesner A, Pa\u015bko P, Kujawska M. How to optimize the effectiveness and safety of Parkinson\u2019s disease therapy?\u2014a systematic review of drugs interactions with food and dietary supplements. Curr Neuropharmacol. 2022;20:1427\u201347.","journal-title":"Curr Neuropharmacol"},{"key":"1511_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s002280050280","volume":"52","author":"S Jaruratanasirikul","year":"1997","unstructured":"Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol. 1997;52:235\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"1511_CR42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0011-393X(97)80016-1","volume":"58","author":"D Lange","year":"1997","unstructured":"Lange D, Pavao JH, Jacqmin P, Woestenborghs R, Ding C, Klausner M. The effect of coadministration of a cola beverage on the bioavailability of itraconazole in patients with acquired immunodeficiency syndrome. Curr Ther Res Clin Exp. 1997;58:202\u201312.","journal-title":"Curr Ther Res Clin Exp"},{"key":"1511_CR43","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0091270010365557","volume":"51","author":"SK Bae","year":"2011","unstructured":"Bae SK, Park SJ, Shim EJ, Mun JH, Kim EY, Shin JG, et al. Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants. J Clin Pharmacol. 2011;51:444\u201351.","journal-title":"J Clin Pharmacol"},{"key":"1511_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2165\/11592630-000000000-00000","volume":"50","author":"J Walravens","year":"2011","unstructured":"Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet. 2011;50:725\u201334.","journal-title":"Clin Pharmacokinet"},{"key":"1511_CR45","first-page":"306","volume":"36","author":"M Kawakami","year":"1998","unstructured":"Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther. 1998;36:306\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1511_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0022-3476(83)80549-6","volume":"102","author":"CM Ginsburg","year":"1983","unstructured":"Ginsburg CM, McCracken GH Jr, Petruska M, Olsen K. Clinical and laboratory observations. Effect of feeding on bioavailability of griseofulvin in children. J Pediatr. 1983;102:309\u201311.","journal-title":"J Pediatr"},{"key":"1511_CR47","first-page":"245","volume":"29","author":"S Zakhari","year":"2006","unstructured":"Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Res Health. 2006;29:245\u201354.","journal-title":"Alcohol Res Health"},{"key":"1511_CR48","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cbi.2004.03.003","volume":"147","author":"K Monostory","year":"2004","unstructured":"Monostory K, Hazai E, Vereczkey L. Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004;147:331\u201340.","journal-title":"Chem Biol Interact"},{"key":"1511_CR49","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1248\/bpb.28.1813","volume":"28","author":"T Niwa","year":"2005","unstructured":"Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1813\u20136.","journal-title":"Biol Pharm Bull"},{"key":"1511_CR50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.36519\/idcm.2023.277","volume":"5","author":"N Dayan","year":"2023","unstructured":"Dayan N, O\u011fral\u0131 E, Kiri\u015f\u00e7io\u011flu C, Dude UK, Er\u015fahin R. Single-dose crossover comparative bioavailability study of two different posaconazole 100\u00a0mg gastro-resistant tablets under fasted and fed conditions in healthy volunteers. Infect Dis Clin Microbiol. 2023;5:341\u201352.","journal-title":"Infect Dis Clin Microbiol"},{"key":"1511_CR51","doi-asserted-by":"publisher","first-page":"S414","DOI":"10.1093\/ofid\/ofy210.1185","volume":"5","author":"J Lindsay","year":"2018","unstructured":"Lindsay J, Mudge S. Novel formulation suba-itraconazole in fed and fasted healthy volunteers: expanding the clinical utility of the established mold active agent. Open Forum Infect Dis. 2018;5:S414\u20135.","journal-title":"Open Forum Infect Dis"},{"key":"1511_CR52","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/j.1875-9114.1996.tb02973.x","volume":"16","author":"VJ Van de Velde","year":"1996","unstructured":"Van de Velde VJ, Van Peer AP, Heykants JJ, Woestenborghs RJ, Van Rooy P, De Beule KL, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy. 1996;16:424\u20138.","journal-title":"Pharmacotherapy"},{"key":"1511_CR53","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/j.1552-4604.1997.tb04332.x","volume":"37","author":"D Lange","year":"1997","unstructured":"Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37:535\u201340.","journal-title":"J Clin Pharmacol"},{"key":"1511_CR54","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1128\/AAC.39.8.1671","volume":"39","author":"TWF Chin","year":"1995","unstructured":"Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39:1671\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR55","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1128\/AAC.01034-08","volume":"53","author":"G Krishna","year":"2009","unstructured":"Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958\u201366.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00228-007-0417-y","volume":"64","author":"PO Gubbins","year":"2008","unstructured":"Gubbins PO, Gurley BJ, Williams DK, Penzak SR, McConnell SA, Franks AM, et al. Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice. Eur J Clin Pharmacol. 2008;64:293\u2013301.","journal-title":"Eur J Clin Pharmacol"},{"key":"1511_CR57","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1592\/phco.24.5.460.33350","volume":"24","author":"PO Gubbins","year":"2004","unstructured":"Gubbins PO, McConnell SA, Gurley BJ, Fincher TK, Franks AM, Williams DK, et al. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Pharmacotherapy. 2004;24:460\u20137.","journal-title":"Pharmacotherapy"},{"key":"1511_CR58","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/antibiotics12050884","volume":"12","author":"A Carmo","year":"2023","unstructured":"Carmo A, Rocha M, Pereirinha P, Tom\u00e9 R, Costa E. Antifungals: from pharmacokinetics to clinical practice. Antibiotics. 2023;12:884.","journal-title":"Antibiotics"},{"key":"1511_CR59","doi-asserted-by":"crossref","unstructured":"Abuhelwa AY, Foster DJR, Mudge S, Hayes D, Upton RN. 10850703 study. In: Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59:5681\u201396.","DOI":"10.1128\/AAC.00973-15"},{"key":"1511_CR60","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejps.2008.07.002","volume":"35","author":"IS Ahmed","year":"2008","unstructured":"Ahmed IS, Aboul-Einien MH, Mohamed OH, Farid SF. Relative bioavailability of griseofulvin lyophilized dry emulsion tablet vs. immediate release tablet: a single-dose, randomized, open-label, six-period, crossover study in healthy adult volunteers in the fasted and fed states. Eur J Pharm Sci. 2008;35:219\u201325.","journal-title":"Eur J Pharm Sci"},{"key":"1511_CR61","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1248\/bpb1978.5.120","volume":"5","author":"N Aoyagi","year":"1982","unstructured":"Aoyagi N, Ogata H, Kaniwa N, Ejima A. Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets. J Pharmacobiodyn. 1982;5:120\u20134.","journal-title":"J Pharmacobiodyn"},{"key":"1511_CR62","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/AAC.37.4.778","volume":"37","author":"JA Barone","year":"1993","unstructured":"Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993;37:778\u201384.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR63","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/j.1875-9114.1998.tb03856.x","volume":"18","author":"JA Barone","year":"1998","unstructured":"Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy. 1998;18:295\u2013301.","journal-title":"Pharmacotherapy"},{"key":"1511_CR64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1128\/AAC.21.1.151","volume":"21","author":"C Brass","year":"1982","unstructured":"Brass C, Galgiani JN, Blaschke TF, Defelice R, O\u2019Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982;21:151\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR65","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/cpdd.1248","volume":"12","author":"N Chen","year":"2023","unstructured":"Chen N, He Q, Ma Y, Liu S, Wei H, Peng A. Pharmacokinetics and bioequivalence of fluconazole capsules manufactured in France and China in healthy Chinese participants: open-label, randomized, single-dose, 2-way, crossover bioequivalence study under fasted and fed conditions. Clin Pharmacol Drug Dev. 2023;12:572\u20138.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1511_CR66","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","volume":"57","author":"R Courtney","year":"2003","unstructured":"Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2003;57:218\u201322.","journal-title":"Br J Clin Pharmacol"},{"key":"1511_CR67","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","volume":"48","author":"R Courtney","year":"2004","unstructured":"Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48:804\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR68","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/jid.1961.154","volume":"37","author":"RG Crounse","year":"1961","unstructured":"Crounse RG. Human Pharmacology of Griseofulvin: the effect of fat intake on gastrointestinal absorption. J Invest Dermatol. 1961;37:529\u201333.","journal-title":"J Invest Dermatol"},{"key":"1511_CR69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1001\/archderm.1963.01590140038006","volume":"87","author":"RG Crounse","year":"1963","unstructured":"Crounse RG. Effective use of griseofulvin. Arch Dermatol. 1963;87:176\u20138.","journal-title":"Arch Dermatol"},{"key":"1511_CR70","first-page":"518","volume":"33","author":"M Cusato","year":"2011","unstructured":"Cusato M, Villani P, Castagnola C, Gotti M, Zappasodi P, Ubezio M. Posaconazole therapeutic drug monitoring in patients with acute myeloid leukemia. Ther Drug Monit. 2011;33:518\u20139.","journal-title":"Ther Drug Monit"},{"key":"1511_CR71","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/cpt1978243333","volume":"24","author":"RE Cutler","year":"1978","unstructured":"Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24:333\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"1511_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.25.1.1","volume":"25","author":"TK Daneshmend","year":"1984","unstructured":"Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, et al. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother. 1984;25:1\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR73","first-page":"S42","volume":"95","author":"P Dogterom","year":"2014","unstructured":"Dogterom P, Van Iersel M, Xu J, Waskin H, Kersemaekers W. The effect of food on the posaconazole pharmacokinetics investigated during the development of a new tablet formulation. Clin Pharmacol Ther. 2014;95:S42.","journal-title":"Clin Pharmacol Ther"},{"key":"1511_CR74","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10096-011-1288-9","volume":"31","author":"C Eiden","year":"2011","unstructured":"Eiden C, Meniane JC, Peyri\u00e8re H, Eymard-Duvernay S, Le Falher G, Ceballos P, et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis. 2011;31:161\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1511_CR75","first-page":"172","volume":"97","author":"M Gotti","year":"2012","unstructured":"Gotti M, Da Vi\u00e0 MC, Zappasodi P, Bonfichi M, Cusato M, Regazzi M, et al. Pharmacokinetic assessment of posaconazole supports an effective anti-fungal prophylaxis in acute myeloid leukemia patients. Haematologica. 2012;97:172.","journal-title":"Haematologica"},{"key":"1511_CR76","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/j.xphs.2016.03.027","volume":"105","author":"B Hens","year":"2016","unstructured":"Hens B, Corsetti M, Brouwers J, Augustijns P. Gastrointestinal and systemic monitoring of posaconazole in humans after fasted and fed state administration of a solid dispersion. J Pharm Sci. 2016;105:2904\u201312.","journal-title":"J Pharm Sci"},{"key":"1511_CR77","unstructured":"Medicines and Healthcare products Regulatory Agency. HGN007 study\u2014a single-dose, four-way crossover, relative bioavailability study to compare the pharmacokinetics of the test product Lozanoc 50 mg hard capsules versus the reference product Sporanox 100 mg capsules in healthy adult volunteers under fed and fasted conditions. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/c86c25a27a87210e71b30f469ae86a729f4cb575. Accessed 10 Aug 2024."},{"key":"1511_CR78","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0378-5173(01)00867-5","volume":"229","author":"SG Kapsi","year":"2001","unstructured":"Kapsi SG, Ayres JW. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm. 2001;229:193\u2013203.","journal-title":"Int J Pharm"},{"key":"1511_CR79","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1128\/AAC.05000-14","volume":"59","author":"WM Kersemaekers","year":"2015","unstructured":"Kersemaekers WM, Dogterom P, Xu J, Marcantonio EE, de Greef R, Waskin H, et al. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother. 2015;59:3385\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR80","first-page":"692","volume":"36","author":"N Khalafalla","year":"1981","unstructured":"Khalafalla N, Elgholmy ZA, Khalil SA. Influence of high fat diet on GI absorption of griseofulvin tablets in man. Pharmazie. 1981;36:692\u20133.","journal-title":"Pharmazie"},{"key":"1511_CR81","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1128\/AAC.02448-13","volume":"58","author":"WK Kraft","year":"2014","unstructured":"Kraft WK, Chang PS, van Iersel MLPS, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58:4020\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR82","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","volume":"28","author":"G Krishna","year":"2008","unstructured":"Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy. 2008;28:1223\u201332.","journal-title":"Pharmacotherapy"},{"key":"1511_CR83","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1128\/AAC.00889-09","volume":"53","author":"G Krishna","year":"2009","unstructured":"Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother. 2009;53:4749\u201352.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR84","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1128\/AAC.00222-12","volume":"56","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Martinho M, O\u2019Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56:4196\u2013201.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR85","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40261-019-00833-1","volume":"39","author":"H Li","year":"2019","unstructured":"Li H, Wei Y, Zhang S, Xu L, Jiang J, Qiu Y, et al. Pharmacokinetics and safety of posaconazole administered by intravenous solution and oral tablet in healthy Chinese subjects and effect of food on tablet bioavailability. Clin Drug Investig. 2019;39:1109\u201316.","journal-title":"Clin Drug Investig"},{"key":"1511_CR86","first-page":"910","volume":"25","author":"Z Li","year":"2020","unstructured":"Li Z, Liu J, Qiu W, Chen H. Bioequivalence of fluconazole capsules in healthy Chinese subjects. Chin J Clin Pharmacol Ther. 2020;25:910\u20135.","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"1511_CR87","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/FTD.0b013e3182818a56","volume":"35","author":"T-Y Lin","year":"2013","unstructured":"Lin T-Y, Yang M-H, Chang F-Y. A randomized, phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400\u00a0mg posaconazole oral suspension in healthy male Taiwanese subjects. Ther Drug Monit. 2013;35:223\u20137.","journal-title":"Ther Drug Monit"},{"key":"1511_CR88","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2710.2005.00632.x","volume":"30","author":"M Lohitnavy","year":"2005","unstructured":"Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30:201\u20136.","journal-title":"J Clin Pharm Ther"},{"key":"1511_CR89","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1128\/AAC.21.5.730","volume":"21","author":"PT M\u00e4nnist\u00f6","year":"1982","unstructured":"M\u00e4nnist\u00f6 PT, M\u00e4ntyl\u00e4 R, Nyk\u00e4nen S, Lamminsivu U, Ottoila P. Impairing effect of food on ketoconazole absorption. Antimicrob Agents Chemother. 1982;21:730\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR90","unstructured":"Center for Drug Evaluation and Research. MPG017 study\u2014TOLSURA capsules 130 mg [2 X 65 mg] administered under fed and fasted conditions in 24 healthy volunteers. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208901Orig1s000MultidisciplineR.pdf. Accessed 12 Aug 2024."},{"key":"1511_CR91","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/(SICI)1099-081X(199703)18:2<127::AID-BDD6>3.0.CO;2-8","volume":"18","author":"J Nedelman","year":"1997","unstructured":"Nedelman J, Cramer JA, Robbins B, Gibiansky E, Chang CT, Gareffa S, et al. The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects. Biopharm Drug Dispos. 1997;18:127\u201338.","journal-title":"Biopharm Drug Dispos"},{"key":"1511_CR92","unstructured":"Tradename (Sanico). Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022484s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"1511_CR93","unstructured":"Brexafemme (Scynexis). Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214900s002lbl.pdf. Accessed 12 Aug 2024."},{"key":"1511_CR94","unstructured":"Vivjoa (Mycovia Pharmaceuticals) Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215888s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"1511_CR95","unstructured":"Noxafil (Merck & Co.) Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205053s1lbl.pdf. Accessed 12 Aug 2024."},{"key":"1511_CR96","unstructured":"Vfend (Pfizer) Prescr. information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021266s039,021267s050,021630s029lbl.pdf. Accessed 12 Aug 2024."},{"key":"1511_CR97","doi-asserted-by":"publisher","first-page":"369","DOI":"10.11150\/kansenshogakuzasshi.83.369","volume":"83","author":"T Oguma","year":"2009","unstructured":"Oguma T, Tabata H, Aihara K, Matsumoto M, Kagioka H, Nagano M, et al. Influence of black vinegar on itraconazole absorption. Kansenshogaku Zasshi. 2009;83:369\u201374.","journal-title":"Kansenshogaku Zasshi"},{"key":"1511_CR98","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.2042-7158.1985.tb05065.x","volume":"37","author":"FA Ogunbona","year":"1985","unstructured":"Ogunbona FA, Smith IF, Olawoye OS. Fat contents of meals and bioavailability of griseofulvin in man. J Pharm Pharmacol. 1985;37:283\u20134.","journal-title":"J Pharm Pharmacol"},{"key":"1511_CR99","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/00007691-199906000-00009","volume":"21","author":"SR Penzak","year":"1999","unstructured":"Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit. 1999;21:304\u20139.","journal-title":"Ther Drug Monit"},{"key":"1511_CR100","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1128\/AAC.50.5.1881-1883.2006","volume":"50","author":"A Sansone-Parsons","year":"2006","unstructured":"Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother. 2006;50:1881\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR101","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5414\/CP202434","volume":"54","author":"A Schmitt-Hoffmann","year":"2016","unstructured":"Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54:572\u201380.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1511_CR102","first-page":"6","volume":"54","author":"M Tei","year":"2006","unstructured":"Tei M, Yamamoto M, Inoue K, Torii S. Single- and multiple-dose pharmacokinetics of itraconazole oral solution in healthy men. Jpn J Chemother. 2006;54:6\u201317.","journal-title":"Jpn J Chemother"},{"key":"1511_CR103","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1128\/AAC.34.10.2032","volume":"34","author":"JE Thorpe","year":"1990","unstructured":"Thorpe JE, Baker N, Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother. 1990;34:2032\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR104","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1128\/AAC.01177-12","volume":"56","author":"M Vaes","year":"2012","unstructured":"Vaes M, Hites M, Cotton F, Bourguignon AM, Cserg\u00f6 M, Rasson C, et al. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrob Agents Chemother. 2012;56:6298\u2013303.","journal-title":"Antimicrob Agents Chemother"},{"key":"1511_CR105","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/BF00558308","volume":"36","author":"A Van Peer","year":"1989","unstructured":"Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol. 1989;36:423\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"1511_CR106","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1034\/j.1399-0012.2001.150206.x","volume":"15","author":"S Wimberley","year":"2001","unstructured":"Wimberley S, Haug M III, Shermock K, Qu A, Maurer J, Mehta A, et al. Enhanced cyclosporine\u2013itraconazole interaction with cola in lung transplant recipients. Clin Transplant. 2001;15:116\u201322.","journal-title":"Clin Transplant"},{"key":"1511_CR107","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0190-9622(87)70194-7","volume":"17","author":"JM Wishart","year":"1987","unstructured":"Wishart JM. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol. 1987;17:220\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR108","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejps.2007.11.001","volume":"33","author":"JS Woo","year":"2008","unstructured":"Woo JS, Song Y-K, Hong J-Y, Lim S-J, Kim C-K. Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Eur J Pharm Sci. 2008;33:159\u201365.","journal-title":"Eur J Pharm Sci"},{"key":"1511_CR109","first-page":"173","volume":"68","author":"HR Xu","year":"2013","unstructured":"Xu HR, Chu NN, Chen WL, Wang ZD, Li XN. Liquid chromatography-mass spectrometry method for the quantification of posaconazole in human plasma: application to pharmacokinetics following single-dose administration in the fasted state and with a high-fat meal. Pharmazie. 2013;68:173\u20137.","journal-title":"Pharmazie"},{"key":"1511_CR110","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00228-006-0200-5","volume":"62","author":"H Yun","year":"2006","unstructured":"Yun H, Baek MS, Park IS, Choi BK, Kwon K. Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers. Eur J Clin Pharmacol. 2006;62:1033\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1511_CR111","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF00199879","volume":"46","author":"T Zimmermann","year":"1994","unstructured":"Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;46:147\u201350.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01511-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:06:53Z","timestamp":1749668813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01511-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01511-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"15 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data supporting the findings of this study are available within the paper and its Supplementary Information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Conceptualization: Pawe\u0142 Pa\u015bko, Agnieszka Wiesner-Kie\u0142czewska, Pawe\u0142 Zagrodzki; systematic literature search: Agnieszka Wiesner-Kie\u0142czewska, Pawe\u0142 Pa\u015bko; data collection and extraction: Agnieszka Wiesner-Kie\u0142czewska, Pawe\u0142 Pa\u015bko; study risk of bias assessment: Agnieszka Wiesner-Kie\u0142czewska, Pawe\u0142 Pa\u015bko, data analysis, and interpretation: Agnieszka Wiesner-Kie\u0142czewska; writing\u2014original draft preparation: Agnieszka Wiesner-Kie\u0142czewska; writing\u2014review and editing: Agnieszka Wiesner-Kie\u0142czewska, Pawe\u0142 Pa\u015bko, Pawe\u0142 Zagrodzki; supervision: Pawe\u0142 Pa\u015bko. All authors read and approved the final version of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}